Search

Your search keyword '"Molina Infante, J"' showing total 460 results
Start Over Author "Molina Infante, J"
460 results on '"Molina Infante, J"'

1. Gastrointestinal fate of proteins from commercial plant–based meat analogs: Silent passage through the stomach, oxidative stress in intestine, and gut dysbiosis in Wistar rats.

Author

Sánchez‐Terrón, G., Martínez, R., Freire, M. J., Molina‐Infante, J., and Estévez, M.

Subjects
DIETARY proteins, MEAT alternatives, LABORATORY rats, MEAT, GASTROINTESTINAL system, VEGETARIAN foods, PROCESSED foods
Abstract

Plant‐based meat analogs (PBMAs) are common ultra‐processed foods (UPFs) included in the vegan/vegetarian diets as presumed healthy alternatives to meat and meat products. However, such health claims need to be supported by scientific evidence. To gain further insight into this topic, two commercial UPFs typically sold as meat analogs, namely, seitan (S) and tofu (T), were included in a cereal‐based chow and provided to Wistar rats for 10 weeks. A group of animals had, simultaneously, an isocaloric and isoprotein experimental diet formulated with cooked beef (B). In all cases, experimental chows (∼4 kcal/g feed) had their basal protein concentration increased from 14% to 30% using proteins from S, T, or B. Upon slaughter, in vivo protein digestibility was assessed, and the entire gastrointestinal tract (digests and tissues) was analyzed for markers of oxidative stress and untargeted metabolomics. Metagenomics was also applied to assess the variation of microbiota composition as affected by dietary protein. Diets based on PBMAs showed lower protein digestibility than those containing meat and promoted an intense luminal glycoxidative stress and an inflammatory intestinal response. The fermentation of undigested oxidized proteins from T in the colon of Wistar rats likely led to formation of mutagenic metabolites such as p‐cresol. The presence of these compounds in the animal models raises concerns about the potential effects of full replacement of meat by certain PBMAs in the diet. Therefore, future research might target on translational human studies to shed light on these findings. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

2. Ultra‐processed vegan foods: Healthy alternatives to animal‐source foods or avoidable junk?

Author

Estévez, Mario, Arjona, A., Sánchez‐Terrón, G., Molina‐Infante, J., and Martínez, R.

Subjects
FOOD industry, JUNK food, MANUFACTURING processes, VEGAN cooking, ESSENTIAL nutrients, PROCESSED foods
Abstract

Animal‐source foods (ASFs), namely, meat, milk, eggs, and derived products, are crucial components of a well‐balanced diet owing to their contribution with multiple essential nutrients. The benefits of the consumption of ASFs in terms of hedonic responses, emotional well‐being, and mood are also widely documented. However, an increasing share of consumers decide to exclude ASFs from their diets. Some of these vegan consumers are inclined to consume so‐called "meat" and/or "dairy analogs," which are produced from plant materials (soy, wheat, and oat, among others). In order to simulate appearance, texture, and flavor of ASFs, these industrial vegan foods are designed using an intricate formulation and industrial processing, which justifies their identification as ultraprocessed foods (UPFs). While the introduction of these processed vegan products is becoming popular in developed countries, the consequences of the sustained intake of these products on human health are mostly ignored. Contrarily to common belief, which emphasizes their role as "healthy" alternatives to ASFs, these plant‐based UPFs may enclose certain threats, which are reviewed in the present paper. The remarkable differences between vegan UPFs and the genuine ASFs (meat/dairy products) from sensory, nutritional, hedonic, or health perspectives precludes the designation of the former as analogs of the latter. Understanding the basis of these differences would contribute to (i) providing consumers with grounds to make reasoned decisions to consume meat/dairy products and/or the vegan alternatives and (ii) providing food companies with strategies to produce more appealing, nutritive, and healthy industrially processed vegan products. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. The Role of Statins on Helicobacter pylori Eradication: Results from the European Registry on the Management of H. pylori (Hp-EuReg)

Author

Caldas M., Perez-Aisa A., Tepes B., Keco-Huerga A., Bujanda L., Lucendo A. J., Rodrigo L., Vaira D., Fernandez-Salazar L., Huguet J. M., Perez-Lasala J., Jurecic N. B., Fadeenko G., Barrio J., Areia M., Ortuno J., Pellicano R., Leja M., Molina-Infante J., Bogomolov P., Alekseenko S., Dominguez-Cajal M., Gomez-Camarero J., Ntouli V., Martinez-Dominguez S. J., Ruiz-Zorrilla R., Nunez O., Silkanovna Sarsenbaeva A., Almela P., Phull P., Espada M., Puig I., Nyssen O. P., Megraud F., O'Morain C., Gisbert J. P., the HP-EuReg Investigators, Gravina AG, Romano M., Caldas M., Perez-Aisa A., Tepes B., Keco-Huerga A., Bujanda L., Lucendo A.J., Rodrigo L., Vaira D., Fernandez-Salazar L., Huguet J.M., Perez-Lasala J., Jurecic N.B., Fadeenko G., Barrio J., Areia M., Ortuno J., Pellicano R., Leja M., Molina-Infante J., Bogomolov P., Alekseenko S., Dominguez-Cajal M., Gomez-Camarero J., Ntouli V., Martinez-Dominguez S.J., Ruiz-Zorrilla R., Nunez O., Silkanovna Sarsenbaeva A., Almela P., Phull P., Espada M., Puig I., Nyssen O.P., Megraud F., O'Morain C., Gisbert J.P., Caldas, M., Perez-Aisa, A., Tepes, B., Keco-Huerga, A., Bujanda, L., Lucendo, A. J., Rodrigo, L., Vaira, D., Fernandez-Salazar, L., Huguet, J. M., Perez-Lasala, J., Jurecic, N. B., Fadeenko, G., Barrio, J., Areia, M., Ortuno, J., Pellicano, R., Leja, M., Molina-Infante, J., Bogomolov, P., Alekseenko, S., Dominguez-Cajal, M., Gomez-Camarero, J., Ntouli, V., Martinez-Dominguez, S. J., Ruiz-Zorrilla, R., Nunez, O., Silkanovna Sarsenbaeva, A., Almela, P., Phull, P., Espada, M., Puig, I., Nyssen, O. P., Megraud, F., O'Morain, C., Gisbert, J. P., the HP-EuReg, Investigator, Gravina, Ag, and Romano, M.

Subjects
Microbiology (medical), medicine.medical_specialty, Multivariate analysis, Helicobacter pylori, statins, treatment, RM1-950, Biochemistry, Microbiology, Article, statins, Rescue therapy, Internal medicine, In real life, Medicine, Pharmacology (medical), General Pharmacology, Toxicology and Pharmaceutics, Helicobacter pylori, treatment, biology, business.industry, Statin, Statin treatment, biology.organism_classification, Treatment, Infectious Diseases, Therapeutics. Pharmacology, business
Abstract

Statins could increase the effectiveness of Helicobacter pylori eradication therapies due to their anti-inflammatory effect. The aim of this study was to analyze the impact of this therapeutic association in real life. This is a multicenter, prospective, non-interventional study aimed at evaluating the management of H. pylori by European gastroenterologists. Patients were registered in an e-CRF by AEG-REDCap from 2013 to 2020. The association between statin use and H. pylori eradication effectiveness was evaluated through multivariate analysis. Overall, 9988 and 705 patients received empirical and culture-guided treatment, respectively. Overall, statin use was associated with higher effectiveness in the empirical group (OR = 1.3, 95%CI = 1.1–1.5), but no association was found with first-line treatment effectiveness (N = 7738), as an exception, statin use was specifically associated with lower effectiveness of standard triple therapy (OR = 0.76, 95%CI = 0.59–0.99). In the rescue therapy empirical group (N = 2228), statins were associated with higher overall effectiveness (OR = 1.9, 95%CI = 1.4–2.6). However, sub-analyses by treatment schemes only confirmed this association for the single-capsule bismuth quadruple therapy (OR = 2.8, 95%CI = 1.3–5.7). No consistent association was found between statin use and H. pylori therapy effectiveness. Therefore, the addition of statins to the usual H. pylori treatment cannot be currently recommended to improve cure rates.

Published
2021

6. European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients

Author

Nyssen OP, Bordin D, Tepes B, Pérez-Aisa Á, Vaira D, Caldas M, Bujanda L, Castro-Fernandez M, Lerang F, Leja M, Rodrigo L, Rokkas T, Kupcinskas L, Pérez- Lasala J, Jonaitis L, Shvets O, Gasbarrini A, Simsek H, Axon ATR, Buzás G, Machado JC, Niv Y, Boyanova L, Goldis A, Lamy V, Tonkic A, Przytulski K, Beglinger C, Venerito M, Bytzer P, Capelle L, Milosavljević T, Milivojevic V, Veijola L, Molina-Infante J, Vologzhanina L, Fadeenko G, Ariño I, Fiorini G, Garre A, Garrido J, F Pérez C, Puig I, Heluwaert F, Megraud F, O'Morain C, Gisbert JP, Romano M, Universidad Autónoma de Madrid (UAM), AS Loginov Moscow Clinical Scientific Center [Moscow, Russian Federation], A.I. Yevdokimov Moscow State University of Medicine and Dentistry [Moscow, Russian Federation], AM DC Rogaska [Rogaska Slatina, Slovenia], Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), University of Bologna/Università di Bologna, Universidad del Pais Vasco / Euskal Herriko Unibertsitatea [Espagne] (UPV/EHU), Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas y Digestivas (CIBERehd), Liver Unit, Clínica Universitaria, CIBER-EHD, Østfold Hospital, University of Latvia (LU), Universidad de Oviedo [Oviedo], Henry Dunant Hospital [Athens, Greece], Lithuanian University of Health Sciences [Kaunas, Lithuania], Hospital Universitario HM Sanchinarro [Madrid, Spain], Università cattolica del Sacro Cuore = Catholic University of the Sacred Heart [Roma] (Unicatt), Faculty of Medicine [Hacettepe University], Hacettepe University = Hacettepe Üniversitesi, Leeds General Infirmary (LGI), Leeds Teaching Hospitals NHS Trust, Ferencváros Health Centre [Budapest, Hungary], Faculdade de Medicina da Universidade do Porto (FMUP), Universidade do Porto = University of Porto, Tel Aviv University (TAU), Medical University of Sofia [Bulgarie], Timisoara Hospital [Timisoara, Romania], Centre Hospitalier Universitaire de Charleroi, University of Split, Medical Centre for Postgraduate Education [Warsaw, Poland], University Hospital Basel [Basel], Otto-von-Guericke-Universität Magdeburg = Otto-von-Guericke University [Magdeburg] (OVGU), Copenhagen University Hospital, Meander Medical Center [Amersfoort, Netherlands], University of Belgrade [Belgrade], Herttoniemi Hospital [Helsinki, Finland], San Pedro de Alcantara Hospital [Cáceres, Espagne], Gastrocentr [Perm, Russian Federation], Digestive Ukrainian Academy of Medical Sciences [Kyiv, Ukraine], Hospital Clínico Universitario 'Lozano Blesa' [Zaragoza, Spain], Althaia Xarxa Assistencial Universitària de Manresa [Manresa, Spain], Universitat de Vic-Universitat Central de Catalunya [Manresa, Spain] (UVicUCC), Complejo Hospitalario Universitario de Santiago de Compostela [Saint-Jacques-de-Compostelle, Espagne] (CHUS), Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois], Physiopathologie du cancer du foie, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Pellegrin, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Trinity College Dublin, Hp-EuReg Investigators: Jen Hinojosa, Inmaculada Santaella, Nuria Fernandez Moreno, Ilaria Maria Saracino, Horacio Alonso Galán, Almudena Durán, Jennifer Fernandez Pacheco, Miroslav Vujasinovic, Rinaldo Pellicano Molinette, Zdenko Kikec, Pedro-Luis Gonzalez Cordero, Maia Donday, Polona Lampic, Vid Leban, Aleksander Gruncic Krajnc, Natasa Brglez Jurecic, Galyna Dmytrivna Fadieienko, Lorena Lee, Irene V Barbado, Alfredo José Lucendo, Alfredo José Lucendo, Jesus Barrio RIo Hortega, Tatiana Alekseevna Ilchishina, Irina Voynovan, Luis Ignacio Fernández-Salazar, Jose María Huguet, Pilar Canelles, Aiman Silkanovna Sarsenbaeva, Ines Modolell Consorci, Pedro Almela, Marina Roldán Lafuente, Josep Maria Botargues, Miguel Areia, Luís Elvas, Susana Isabel Alves, Daniel Brito, Ana Teresa Cadime, Sandra Lúcia Madeira Saraiva, Charalampos Tzathas, Vassiliki Ntouli, Alicia C Marin, Cem Simsek, Alba Rocco, Juan Antonio Ortuño, Tommaso Di Maira, Sotirios D Georgopoulos, Stephan Brackmann, Vendel Kristensen Lovisenberg, Blas Jose Gomez-Rodriguez, Perminder Singh Phull, Sergey Alekseyevich, Monica Perona, Rustam Abdulkhakov, Deirdre McNamara, Sinead M Smith, Denise Elizabeth Brennan, Marina Fedorovna Osipenko, Cristobal de la Coba, Pilar Varela, Maria Anatolyevna Livzan, Oleg V Zaytsev, Vladislav Vladimirovich Tsukanov, Alexander Viktorovich Vasyutin, Olga Sergeevna Amelchugova, Spiros Michopoulus, Sergey Gennadievich Burkov, Dan Dumitrascu, Bogdan Ianosi, Ingrid Prytz Berset, Rafael Ruiz-Zorrilla Lopez, Charo Antón, Anne Courillon-Mallet, Natasa Brglez Jurecic, Judith Gomez-Camarero, Manuel Jimenez-Moreno, Ahmet Uygun, Ian Leonard Phillip Beales, Alain Huerta-Madrigal, Javier Alcedo, Mercè Barenys, Francesco Franceschi, Jean-Charles Delchier, Liliana Silvia Pozzati, Monika Augustyn, Maja Seruga, Miriam Hiestand, Patric Mosler, Zaza Beniashvili, Doron Boltin, Hubert Louis, Ramon Pajares, Natalia Valerievna Zakharova, Natalia Nikolaevna Dekhnich, Victor Asparuhov Kamburov, Maria Pina Dore, Lorena Sancho, Oscar Núñez, Katrine Dvergsnes Sørlandet, Peter Malfertheiner, Ana Campillo, Miguel Fernandez-Bermejo, Manuel Domínguez-Cajal, José Luis Domínguez Jiménez, Alicia Algaba, Fernando Bermejo, Borislav Vladimirov, László Czakó, Teresa Angueira, Eduardo Iyo, Ekaterina Yuryevna, Larissa Tarasova, Ludmila Grigorieva, Judith Millastre, Aldis Pukitis, Valeriy Kryvy, Roald Torp, Albert Tomàs, Edurne Amorena, Fermin Estremera, Rossen Nikolov, Asghar Quasim, Yury Aleksandrovich Kucheryavyy, Natalia Baryshnikova, Xavier Calvet, Ariadna Figuerola, Marco Romano, Antonietta Gerarda Gravina, Oscar Núñez, Fazia Mana, Pilar Sánchez-Pobre, Zoya Spassova, Jesús M González-Santiago, Ricardo Marcos-Pinto, F Wolfhagen, Svetlana Cui, Ivonne Leeuwenburgh, Driffa Moussata, Adi Lahat-Zok, Sergii Hryhorovych, Rasmus Goll, Tatyana Vasilyevna, Juris Pokrotnieks, Philippe Émile, Nadiya Byelyayeva, Marta Lozano, Mette Wildner-Christensen, Bengt Odman, Yana Valerieva, Alenka Forte, Antonio Cuadrado, Patrice Pienkowski, Ilze Kikuste, Dag Arne Lihaug Hoff, Jane Moeller Hansen, Konrads Funka, Alla Kononova, Sergey Kolbasnikov, Michael Selgrad, Jolanta Sumskiene, Jonathan Hirsch, Francisco Javier Zozaya Larequi, Alain C Burette, Nora Dancs Petz-Aladar, Janne Rajala Herttoniemi, Christina Reimer, Diogo Libanio, Pedro Pimentel-Nunes, Ivailo Evstatiev, Juozas Kupcinskas, Mikhail Butov, Peter Mensink, T Tang, Andrey Yurevich Baranovsky, Natalya Marchenko, Boris Bastens, Lyudmila Mateva, Dominique Lamarque, Leonardo Henry, Mario Ribeiro, M Ter Borg, Alexander C Ford, Enrique Medina, Manuel Rodriguez-Tellez, Francisco José Rancel, Elisa Martin, Carolina Torres Gonzalez, Lissa Maria Franco, Angel Lanas, Pilar Canelles, Noelia Alcaide, Bruno Richard-Molard, Megraud, Francis, Nyssen O.P., Bordin D., Tepes B., Perez-Aisa A., Vaira D., Caldas M., Bujanda L., Castro-Fernandez M., Lerang F., Leja M., Rodrigo L., Rokkas T., Kupcinskas L., Perez-Lasala J., Jonaitis L., Shvets O., Gasbarrini A., Simsek H., Axon A.T.R., Buzas G., Machado J.C., Niv Y., Boyanova L., Goldis A., Lamy V., Tonkic A., Przytulski K., Beglinger C., Venerito M., Bytzer P., Capelle L., Milosavljevic T., Milivojevic V., Veijola L., Molina-Infante J., Vologzhanina L., Fadeenko G., Arino I., Fiorini G., Garre A., Garrido J., F Perez C., Puig I., Heluwaert F., Megraud F., O'Morain C., Gisbert J.P., Universidad Autonoma de Madrid (UAM), University of Bologna, Università cattolica del Sacro Cuore [Roma] (Unicatt), Universidade do Porto, Tel Aviv University [Tel Aviv], Otto-von-Guericke University [Magdeburg] (OVGU), Nyssen, Op, Bordin, D, Tepes, B, Pérez-Aisa, Á, Vaira, D, Caldas, M, Bujanda, L, Castro-Fernandez, M, Lerang, F, Leja, M, Rodrigo, L, Rokkas, T, Kupcinskas, L, Pérez- Lasala, J, Jonaitis, L, Shvets, O, Gasbarrini, A, Simsek, H, Axon, Atr, Buzás, G, Machado, Jc, Niv, Y, Boyanova, L, Goldis, A, Lamy, V, Tonkic, A, Przytulski, K, Beglinger, C, Venerito, M, Bytzer, P, Capelle, L, Milosavljević, T, Milivojevic, V, Veijola, L, Molina-Infante, J, Vologzhanina, L, Fadeenko, G, Ariño, I, Fiorini, G, Garre, A, Garrido, J, F Pérez, C, Puig, I, Heluwaert, F, Megraud, F, O'Morain, C, Gisbert, Jp, and Romano, M

Subjects
Male, Registrie, Proton Pump Inhibitor, Practice Patterns, 0302 clinical medicine, Clarithromycin, Prospective Studies, Registries, Practice Patterns, Physicians', [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, biology, Gastroenterology, Middle Aged, Anti-Bacterial Agents, 3. Good health, Europe, 030220 oncology & carcinogenesis, Combination, 030211 gastroenterology & hepatology, Drug Therapy, Combination, Female, medicine.drug, Human, Adult, medicine.medical_specialty, TRIPLE THERAPY, QUADRUPLE THERAPY, CONSENSUS, INFECTION, METAANALYSIS, CLARITHROMYCIN, GUIDELINES, RESISTANCE, ARTICLE, Settore MED/12 - GASTROENTEROLOGIA, First line, Helicobacter Infections, 03 medical and health sciences, Drug Therapy, Internal medicine, Anti-Bacterial Agent, medicine, Humans, Medical prescription, Adverse effect, Aged, Physicians', Helicobacter pylori, business.industry, helicobacter pylori - treatment, Proton Pump Inhibitors, Amoxicillin, biology.organism_classification, Metronidazole, Prospective Studie, Concomitant, helicobacter pylori, business, Helicobacter Infection, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

ObjectiveThe best approach for Helicobacter pylori management remains unclear. An audit process is essential to ensure clinical practice is aligned with best standards of care.DesignInternational multicentre prospective non-interventional registry starting in 2013 aimed to evaluate the decisions and outcomes in H. pylori management by European gastroenterologists. Patients were registered in an e-CRF by AEG-REDCap. Variables included demographics, previous eradication attempts, prescribed treatment, adverse events and outcomes. Data monitoring was performed to ensure data quality. Time-trend and geographical analyses were performed.Results30 394 patients from 27 European countries were evaluated and 21 533 (78%) first-line empirical H. pylori treatments were included for analysis. Pretreatment resistance rates were 23% to clarithromycin, 32% to metronidazole and 13% to both. Triple therapy with amoxicillin and clarithromycin was most commonly prescribed (39%), achieving 81.5% modified intention-to-treat eradication rate. Over 90% eradication was obtained only with 10-day bismuth quadruple or 14-day concomitant treatments. Longer treatment duration, higher acid inhibition and compliance were associated with higher eradication rates. Time-trend analysis showed a region-dependent shift in prescriptions including abandoning triple therapies, using higher acid-inhibition and longer treatments, which was associated with an overall effectiveness increase (84%–90%).ConclusionManagement of H. pylori infection by European gastroenterologists is heterogeneous, suboptimal and discrepant with current recommendations. Only quadruple therapies lasting at least 10 days are able to achieve over 90% eradication rates. European recommendations are being slowly and heterogeneously incorporated into routine clinical practice, which was associated with a corresponding increase in effectiveness.

Published
2020
Full Text
View/download PDF

7. Empirical Second-Line Therapy in 5,000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg)

Author

Nyssen OP, Vaira D, Pérez Aísa Á, Rodrigo L, Castro-Fernandez M, Jonaitis L, Tepes B, Vologzhanina L, Caldas M, Lanas A, Lucendo AJ, Bujanda L, Ortuño J, Barrio J, Huguet JM, Voynovan I, Lasala JP, Sarsenbaeva AS, Fernandez-Salazar L, Molina-Infante J, Jurecic NB, Areia M, Gasbarrini A, Kupcinskas J, Bordin D, Marcos-Pinto R, Lerand F, Leja M, Buzas GM, Niv Y, Rokkas T, Phull P, Smith S, Shvets O, Venerito M, Milivojevic V, Simsek I, Lamy V, Bytzer P, Boyanova L, Kunovský L, Beglinger C, Doulberis M, Marlicz W, Goldis A, Tonkic A, Capelle L, Puig I, Megraud F, Morain CO, Gisbert JP, and European Registry on Helicobacter pylori Management Hp-EuReg Investigators

Subjects
Helicobacter pylori, Clarithromycin, Rescue, Levofloxacin, Bismuth
Abstract

BACKGROUND & AIMS: After a first Helicobacter pylori eradication attempt, approximately 20% of patients will remain infected. The aim of the current study was to assess the effectiveness and safety of second-line empiric treatment in Europe. METHODS: This international, multicenter, prospective, noninterventional registry aimed to evaluate the decisions and outcomes of H pylori management by European gastroenterologists. All infected adult cases with a previous eradication treatment attempt were registered with the Spanish Association of Gastroenterology-Research Electronic Data Capture until February 2021. Patients allergic to penicillin and those who received susceptibility-guided therapy were excluded. Data monitoring was performed to ensure data quality. RESULTS: Overall, 5055 patients received empiric second-line treatment. Triple therapy with amoxicillin and levofloxacin was prescribed most commonly (33%). The overall effectiveness was 82% by modified intention-to-treat analysis and 83% in the per-protocol population. After failure of first-line clarithromycin-containing treatment, optimal eradication (>90%) was obtained with moxifloxacin-containing triple therapy or levofloxacin-containing quadruple therapy (with bismuth). In patients receiving triple therapy containing levofloxacin or moxifloxacin, and levofloxacin-bismuth quadruple treatment, cure rates were optimized with 14-day regimens using high doses of proton pump inhibitors. However, 3-in-1 single capsule or levofloxacin-bismuth quadruple therapy produced reliable eradication rates regardless of proton pump inhibitor dose, duration of therapy, or previous first-line treatment. The overall incidence of adverse events was 28%, and most (85%) were mild. Three patients developed serious adverse events (0.3%) requiring hospitalization. CONCLUSIONS: Empiric second-line regimens including 14-day quinolone triple therapies, 14-day levofloxacin-bismuth quadruple therapy, 14-day tetracycline-bismuth classic quadruple therapy, and 10-day bismuth quadruple therapy (as a single capsule) provided optimal effectiveness. However, many other second-line treatments evaluated reported low eradication rates. ClincialTrials.gov number: NCT02328131.

Published
2022

8. The Endoscopic Reference Score shows modest accuracy to predict either clinical or histological activity in adult patients with eosinophilic oesophagitis

Author

Rodríguez‐Sánchez, J., Barrio‐Andrés, J., Nantes Castillejo, O., Valdivieso‐Cortazar, E., Pérez‐Martínez, I., Boumidi, A., Olmos‐Jérez, J. A., Payeras‐Llodra, G., Alcaide‐Suarez, N., Ruiz‐Rebollo, L., Madrigal‐ Rubiales, B., Gonzalez‐Obeso, E., de la Santa Belda, E., López Viedma, B., and Molina‐Infante, J.

Published
2017
Full Text
View/download PDF

9. Third-Line Rescue Therapy with Bismuth-Containing Quadruple Regimen After Failure of Two Treatments (with Clarithromycin and Levofloxacin) for H. pylori Infection

Author

Gisbert, J. P., Perez-Aisa, A., Rodrigo, L., Molina-Infante, J., Modolell, I., Bermejo, F., Castro-Fernández, M., Antón, R., Sacristán, B., Cosme, A., Barrio, J., Harb, Y., Gonzalez-Barcenas, M., Fernandez-Bermejo, M., Algaba, A., Marín, A. C., McNicholl, A. G., and On behalf of the H. pylori Study Group of the Spanish Gastroenterology Association

Published
2014
Full Text
View/download PDF

13. Room for Improvement in the Treatment of Helicobacter pylori Infection: Lessons from the European Registry on H. pylori Management (Hp-EuReg)

Author

Nyssen O. P., Vaira D., Tepes B., Kupcinskas L., Bordin D., Perez-Aisa A., Gasbarrini A., Castro-Fernandez M., Bujanda L., Garre A., Lucendo A. J., Vologzhanina L., Jurecic N. B., Rodrigo-Saez L., Huguet J. M., Voynovan I., Perez-Lasala J., Romero P. M., Vujasinovic M., Abdulkhakov R., Barrio J., Fernandez-Salazar L., Megraud F., O'Morain C., Gisbert J. P., Ilchishina T., Arino I., Zaytsev O., Perona M., Sarsenbaeva A. S., Ortuno J., Alekseenko S., Dominguez-Cajal M., Rodriguez B. J. G., Notari P. A., Pellicano R., Consorci I. M., Nardone G., Bote J. M. B. -A., Nunez O., Gomez-Camarero J., Guadix J. H., Fiorini G., Jonaitis L., Galan H. A., Ferrer L., Molina-Infante J., Kikec Z., Alcaide N., Lanas A., Sant'Orsola V. C., Medina-Chulia E., Canelles P., Santos-Fernandez J., Velayos B., Di Maira T., Lafuente M. R., Moreno M. J., Dekhnich N. N., Varela P., de la Coba C., Osipenko M. F., Lopez R. R. -Z., Huerta-Madrigal A., Livzan M. A., Pozzati L. S., Iyo E., Amelchugova O. S., Vasyutin A. V., Tsukanov V. V., Barenys M., Burkov S. G., Gravina A. G., Romano M., Bakulina N. V., Fernandez-Bermejo M., Alcedo J., Franceschi F., Campillo A., Seruga M., Villarroya R. P., Mego M., Dore M. P., Tito L., Gmez B., Jimenez J. L. D., Bermejo F., Algaba A., Belousova L. N., Plotnikova E. Y., Calvet X., Figuerola A., Tarasova L., Grigorieva L., Amorena E., Estremera F., Sanchez-Pobre P., Millastre J., Tomas A., Baryshnikova N., Kucheryavyy Y. A., Kononova A., Bakulin I., Cerezo F. J. M., Venciene R., Zhestkova T. V., Rocco A., Gonzalez Santiago J. M., Nyssen, O. P., Vaira, D., Tepes, B., Kupcinskas, L., Bordin, D., Perez-Aisa, A., Gasbarrini, A., Castro-Fernandez, M., Bujanda, L., Garre, A., Lucendo, A. J., Vologzhanina, L., Jurecic, N. B., Rodrigo-Saez, L., Huguet, J. M., Voynovan, I., Perez-Lasala, J., Romero, P. M., Vujasinovic, M., Abdulkhakov, R., Barrio, J., Fernandez-Salazar, L., Megraud, F., O'Morain, C., Gisbert, J. P., Ilchishina, T., Arino, I., Zaytsev, O., Perona, M., Sarsenbaeva, A. S., Ortuno, J., Alekseenko, S., Dominguez-Cajal, M., Rodriguez, B. J. G., Notari, P. A., Pellicano, R., Consorci, I. M., Nardone, G., Bote, J. M. B. -A., Nunez, O., Gomez-Camarero, J., Guadix, J. H., Fiorini, G., Jonaitis, L., Galan, H. A., Ferrer, L., Molina-Infante, J., Kikec, Z., Alcaide, N., Lanas, A., Sant'Orsola, V. C., Medina-Chulia, E., Canelles, P., Santos-Fernandez, J., Velayos, B., Di Maira, T., Lafuente, M. R., Moreno, M. J., Dekhnich, N. N., Varela, P., de la Coba, C., Osipenko, M. F., Lopez, R. R. -Z., Huerta-Madrigal, A., Livzan, M. A., Pozzati, L. S., Iyo, E., Amelchugova, O. S., Vasyutin, A. V., Tsukanov, V. V., Barenys, M., Burkov, S. G., Gravina, A. G., Romano, M., Bakulina, N. V., Fernandez-Bermejo, M., Alcedo, J., Franceschi, F., Campillo, A., Seruga, M., Villarroya, R. P., Mego, M., Dore, M. P., Tito, L., Gmez, B., Jimenez, J. L. D., Bermejo, F., Algaba, A., Belousova, L. N., Plotnikova, E. Y., Calvet, X., Figuerola, A., Tarasova, L., Grigorieva, L., Amorena, E., Estremera, F., Sanchez-Pobre, P., Millastre, J., Tomas, A., Baryshnikova, N., Kucheryavyy, Y. A., Kononova, A., Bakulin, I., Cerezo, F. J. M., Venciene, R., Zhestkova, T. V., Rocco, A., Gonzalez Santiago, J. M., Lucendo, A., and the Hp-EuReg, Investigator

Subjects
Registrie, medicine.medical_specialty, Proton Pump Inhibitor, medicine.drug_class, Settore MED/12 - GASTROENTEROLOGIA, Antibiotics, MEDLINE, Helicobacter Infections, 03 medical and health sciences, 0302 clinical medicine, Pharmacotherapy, Drug Therapy, Clarithromycin, Internal medicine, Metronidazole, Anti-Bacterial Agent, bismuth, medicine, non-bismuth, Humans, Prospective Studies, Registries, Disease management (health), levofloxacin, biology, Helicobacter pylori, business.industry, mistake, Gastroenterology, Amoxicillin, Proton Pump Inhibitors, biology.organism_classification, error, Anti-Bacterial Agents, Penicillin, Prospective Studie, 030220 oncology & carcinogenesis, Combination, 030211 gastroenterology & hepatology, Drug Therapy, Combination, business, Helicobacter Infection, H. pylori, medicine.drug, Human
Abstract

BACKGROUND: Managing Helicobacter pylori infection requires constant decision making, and each decision is open to possible errors. AIM: The aim was to evaluate common mistakes in the eradication of H. pylori, based on the "European Registry on Helicobacter pylori management". METHODS: European Registry on Helicobacter pylori management is an international multicentre prospective noninterventional registry evaluating the decisions and outcomes of H. pylori management by European gastroenterologists in routine clinical practice. RESULTS: Countries recruiting more than 1000 patients were included (26,340 patients). The most common mistakes (percentages) were: (1) To use the standard triple therapy where it is ineffective (46%). (2) To prescribe eradication therapy for only 7 to 10 days (69%). (3) To use a low dose of proton pump inhibitors (48%). (4) In patients allergic to penicillin, to prescribe always a triple therapy with clarithromycin and metronidazole (38%). (5) To repeat certain antibiotics after eradication failure (>15%). (6) Failing to consider the importance of compliance with treatment (2%). (7) Not to check the eradication success (6%). Time-trend analyses showed progressive greater compliance with current clinical guidelines. CONCLUSION: The management of H. pylori infection by some European gastroenterologists is heterogeneous, frequently suboptimal and discrepant with current recommendations. Clinical practice is constantly adapting to updated recommendations, although this shift is delayed and slow.

Published
2020

21. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments

Author

Gisbert, J. P., Romano, M., Gravina, A. G., Solís-Muñoz, P., Bermejo, F., Molina-Infante, J., Castro-Fernández, M., Ortuño, J., Lucendo, A. J., Herranz, M., Modolell, I., del Castillo, F., Gómez, J., Barrio, J., Velayos, B., Gómez, B., Domínguez, J. L., Miranda, A., Martorano, M., Algaba, A., Pabón, M., Angueira, T., Fernández-Salazar, L., Federico, A., Marín, A. C., and McNicholl, A. G.

Published
2015
Full Text
View/download PDF

22. Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study

Author

Molina-Infante, J., Lucendo, A. J., Angueira, T., Rodriguez-Tellez, M., Perez-Aisa, A., Balboa, A., Barrio, J., Martin-Noguerol, E., Gomez-Rodriguez, B. J., Botargues-Bote, J. M., Gomez-Camarero, J., Huerta, A., Modolell, I., Ariño, I., Herranz-Bachiller, M. T., Bermejo, F., McNicholl, A. G., OʼMorain, C., Gisbert, J. P., Lima, A., Tejero-Bustos, M. A., Sans, M., Mearin, F., Perez-Lasala, J., Mañas-Gallardo, N., Millastre, J., Gracia, M., Rodriguez-Sanchez, J., Rancel-Medina, F. J., Lanas, A., and Prados, S.

Published
2015
Full Text
View/download PDF

31. Persistent Villous Atrophy in De Novo Adult Patients With Celiac Disease and Strict Control of Gluten-Free Diet Adherence: A Multicenter Prospective Study (CADER Study)

Author

Fernández-Bañares F, Beltrán B, Salas A, Comino I, Ballester-Clau R, Ferrer C, Molina-Infante J, Rosinach M, Modolell I, Rodríguez-Moranta F, Arau B, Segura V, Fernández-Salazar L, Santolaria S, Esteve M, and Sousa C

Subjects
HEPATIC FAT, EXPRESSION, I148M, HISTOLOGICAL SEVERITY, nutritional and metabolic diseases, GENETIC-VARIATION, LIPID DROPLETS, MOUSE-LIVER, WEIGHT-LOSS, digestive system, digestive system diseases, PNPLA3, FATTY LIVER-DISEASE
Abstract

A substantial proportion of adult patients with celiac disease on a gluten-free diet exhibit persistent villous atrophy, and inadvertent gluten exposure may be one of the causes. The aim of the present study was to evaluate villous atrophy persistence after 2 years on a gluten-free diet in de novo adult patients with celiac disease with strict control of gluten exposure.

Published
2021

32. European Registry on Helicobacter pylori management (Hp-EuReg): Patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients

Author

Nyssen, O. P., Bordin, D., Tepes, B., Perez-Aisa, A., Vaira, D., Caldas, M., Bujanda, L., Castro-Fernandez, M., Lerang, F., Leja, M., Rodrigo, L., Rokkas, T., Kupcinskas, L., Perez-Lasala, J., Jonaitis, L., Shvets, O., Gasbarrini, Antonio, Simsek, H., Axon, A. T. R., Buzas, G., Machado, J. C., Niv, Y., Boyanova, L., Goldis, A., Lamy, V., Tonkic, A., Przytulski, K., Beglinger, C., Venerito, M., Bytzer, P., Capelle, L., Milosavljevic, T., Milivojevic, V., Veijola, L., Molina-Infante, J., Vologzhanina, L., Fadeenko, G., Arino, I., Fiorini, G., Garre, A., Garrido, J., F Perez, C., Puig, I., Heluwaert, F., Megraud, F., O'Morain, C., Gisbert, J. P., Gasbarrini A. (ORCID:0000-0002-7278-4823), Nyssen, O. P., Bordin, D., Tepes, B., Perez-Aisa, A., Vaira, D., Caldas, M., Bujanda, L., Castro-Fernandez, M., Lerang, F., Leja, M., Rodrigo, L., Rokkas, T., Kupcinskas, L., Perez-Lasala, J., Jonaitis, L., Shvets, O., Gasbarrini, Antonio, Simsek, H., Axon, A. T. R., Buzas, G., Machado, J. C., Niv, Y., Boyanova, L., Goldis, A., Lamy, V., Tonkic, A., Przytulski, K., Beglinger, C., Venerito, M., Bytzer, P., Capelle, L., Milosavljevic, T., Milivojevic, V., Veijola, L., Molina-Infante, J., Vologzhanina, L., Fadeenko, G., Arino, I., Fiorini, G., Garre, A., Garrido, J., F Perez, C., Puig, I., Heluwaert, F., Megraud, F., O'Morain, C., Gisbert, J. P., and Gasbarrini A. (ORCID:0000-0002-7278-4823)

Abstract

Objective The best approach for Helicobacter pylori management remains unclear. An audit process is essential to ensure clinical practice is aligned with best standards of care. Design International multicentre prospective non-interventional registry starting in 2013 aimed to evaluate the decisions and outcomes in H. pylori management by European gastroenterologists. Patients were registered in an e-CRF by AEG-REDCap. Variables included demographics, previous eradication attempts, prescribed treatment, adverse events and outcomes. Data monitoring was performed to ensure data quality. Time-trend and geographical analyses were performed. Results 30 394 patients from 27 European countries were evaluated and 21 533 (78%) first-line empirical H. pylori treatments were included for analysis. Pretreatment resistance rates were 23% to clarithromycin, 32% to metronidazole and 13% to both. Triple therapy with amoxicillin and clarithromycin was most commonly prescribed (39%), achieving 81.5% modified intention-to-treat eradication rate. Over 90% eradication was obtained only with 10-day bismuth quadruple or 14-day concomitant treatments. Longer treatment duration, higher acid inhibition and compliance were associated with higher eradication rates. Time-trend analysis showed a region-dependent shift in prescriptions including abandoning triple therapies, using higher acid-inhibition and longer treatments, which was associated with an overall effectiveness increase (84%-90%). Conclusion Management of H. pylori infection by European gastroenterologists is heterogeneous, suboptimal and discrepant with current recommendations. Only quadruple therapies lasting at least 10 days are able to achieve over 90% eradication rates. European recommendations are being slowly and heterogeneously incorporated into routine clinical practice, which was associated with a corresponding increase in effectiveness.

Published
2021

43. RANDOMISED CLINICAL TRIAL COMPARING SEQUENTIAL AND CONCOMITANT THERAPIES FOR HELICOBACTER PYLORI ERADICATION IN ROUTINE CLINICAL PRACTICE: Abstract no.: P11.07

Author

McNicholl, A. G., Marin, A. C., Molina-Infante, J., Castro-Fernandez, M., Barrio, J., Ducons, J., Calvet, X., de la Coba, C., Montoro, M., Bory, F., Perez-Aisa, A., Forne, M., Ramas, M., Millan, R., Araguren, P., Garcia-Iglesias, P., Belloc, B., Bessa, X., Sainz, E., Gisbert, J. L., Lamas, E., Marcos, E., Moreno, M. I., Abad-Santos, F., and Gisbert, J. P.

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results